COVID-19 vaccines have been deployed in the UK since December 2020. This article examines the impact of COVID-19 vaccines on transmission of the virus. It also considers the potential implications of vaccine-induced protection for easing lockdown restrictions and debate about potential introduction of immunity certification or a vaccine passport scheme.
In the UK, 40-50% of children have at least one diagnosed allergy. The increased prevalence of allergies negatively impacts affected children’s quality of life and puts pressure on health services. This note discusses the causes and extent of allergic disease in childhood, examines the links between allergy, genetics and the environment and summarises current research.
How does COVID-19 affect children? Will children be vaccinated against the disease? This article summarises the latest findings from research and highlights where more research can explore some of the remaining uncertainties.
On December 31, 2020 the four UK Chief Medical Officers (CMOs) published a statement announcing changes to the dosing schedule for the second dose of the Pfizer/BioNTech and University of Oxford/AstraZeneca vaccines. It stated that the interval between the first and second dose should be extended from 3–4 weeks to up to 12 weeks. This rapid response examines the evidence behind this decision.